Module 9 Quiz

A  Bacterial cells

B  Human cells

C  Fungal cells

D  All cell types

A  Presence of double-stranded DNA

B  Number of chromosomes

C  Number of genes

D  Structure of chromosomes

A  adding nucleotides to primed sites of the DNA strands.

B  binding of the primers to the single-stranded DNA.

C  making a cDNA from an mRNA strand.

D  unwinding and separating the double-stranded DNA.

A  Deletion of a deoxyribonucleotide

B  Addition of a dideoxynucleotide

C  Addition of a ribonucleotide

D  Addition of a deoxyribonucleotide

A  Blank control

B  dTTP control

C  Positive control

D  Oligoligated control

A  Polymerase

B  Lysozyme

C  Restriction enzyme

D  Transcriptase

A  sequence of nucleotides that codes for a protein.

B  polymeric molecule composed of nucleic acids.

C  sequence of three nucleotides.

D  phosphate group, a ribose sugar, and nitrogen.

A  Hydroxyl group

B  Phosphate group

C  Methyl group

D  Hydrogen

A  nucleotides.

B  hormones.

C  histones.

D  lysosomes.

A  40%

B  20%

C  30%

D  60%

A  metabolic pattern.

B  toxin effect.

C  pattern constellation.

D  toxidrome.

A  HPLC.

B  immunoassay.

C  spectrophotometry.

D  flame ionization gas chromatography (GC).

A  The myocardial infarction is caused by the effect on respiratory centers in the brain and eventual lack of stimulation of the heart.

B  The coma produced is caused by an immediate decrease in sensitivity to CO2 concentration through depression of respiratory centers in the brain.

C  The metabolic acidosis produced is caused by increased formation of formic acid by the liver during metabolism.

D  The hepatic necrosis is caused by depletion of a substance in the liver and eventual accumulation of the oxidized metabolite.

A  [Na+] − [Cl− +  [HCO3-]

B  [Cl−] + [Na+ +  [HCO3-]

C  [Na+] + [Cl− +  [HCO3-]

D  [HCO3-]  − [Na+ + Cl−].

A  GC-MS.

B  electrophoresis.

C  a spot test.

D  a more sensitive and specific immunoassay procedure.

A  At 8 AM, when liver metabolism is highest.

B  Immediately before a dose of the drug is given.

C  There is no specific time that is the best for blood collection.

D  Immediately after a dose of the drug is given.

A  To monitor significant drug-drug interactions

B  To determine drug concentrations in a pathophysiological state

C  To monitor drugs with a broad therapeutic range

D  To check patient compliance

A  Increased drug metabolism caused by central nervous system disease

B  Using a single drug as opposed to multiple drugs for treatment

C  Using a different route of administration than is typically used for that drug

D  Decreased renal elimination leading to increased free drug concentration

A  Lipoprotein

B  Albumin

C  α1-Glycoprotein

D  Albumin, Lipoprotein, and α1-Glycoprotein

A  dosing curve.

B  half-life.

C  volume of distribution.

D  subtherapeutic range.